跳至主要内容
临床试验/NCT02325869
NCT02325869Unknown不适用

DebriS Interventional REmoval in ACS (DESIRE-ACS) Study to Assess the Safety and Performance of the ECA Bell Balloon in Subjects Undergoing Coronary Percutaneous Interventions.

Angioslide Ltd.2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2015年7月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
30
试验地点
2
主要终点
Angiographic and Device Success

研究概览

简要总结

DebriS Interventional REmoval in ACS (DESIRE-ACS) Study to assess the safety and performance of the ECA Bell balloon in subjects undergoing coronary percutaneous interventions.

详细描述

Coronary arterial disease (CAD) is defined as obstruction of blood flow into the coronary arteries (i.e. the arteries that supply blood to the heart muscle). Patients with symptoms of coronary artery disease usually suffer from stable angina pectoris (chest pain or discomfort), unstable angina pectoris, or a myocardial infarction (heart attack). The symptoms range from mild angina, to moderate or severe angina.

In some cases of CAD the blood vessel is chronically totally blocked (total occlusion), stopping blood flow through the blocked blood vessel. In these cases a minimally invasive treatment or a surgery may be needed. "Minimally invasive procedures" consist of angioplasty or stent placement. The procedure is performed under local anesthetic with the patient lying on their back.

Angioplasty is a routine, well known, non-surgical procedure that is performed by making a small incision of the skin in the groin through which a catheter (narrow tube) and a guidewire (a thin metal wire) are inserted to reach the blocked artery. After reaching the blocked artery and crossing the blockage with a guidewire, a tiny balloon is inflated inside the artery to open the blockage. During the course of this procedure small pieces of the material that is causing the blockage may break off and be carried by the blood stream to other parts of the body where they may lodge and cause damage by blocking the blood flow . The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical criteria
  • Subject is ≥18 years of age.
  • Subject with acute coronary syndrome (STEMI or NSTEMI).
  • Candidate for percutaneous coronary intervention (PCI) in native coronary artery.
  • Anticipated patient life expectancy of at least 1 year since enrollment.
  • Subject is male or a non-pregnant female.
  • Subject has provided written informed consent.
  • Subject is able and willing to adhere to the required follow-up visits and testing.
  • Angiographic Criteria
  • Lesions amendable to PCI.
  • Angiographically thrombotic-appearing lesion that amenable to PCI.
  • Lesion(s) is located within the native vessel and has ≥ 50% but <100% stenosis.
  • The target lesion should be at least 10mm proximal to the proximal edge of a stented lesion.
  • Only a single lesion will be treated by the investigational device.
  • Vessel has thrombolysis in myocardial infarction (TIMI) grade 1 or higher flow before the use of the investigational device.
  • Reference vessel diameter, where the Bell balloon is to be placed, is 3-4mm in diameter by angiographic visual estimation.

排除标准

  • Clinical Criteria
  • Women except those whose menstrual periods have not occurred for more than one year after menopause or those who have had sterilization surgery (tubal ligation) or hysterectomy
  • Known contraindication to the use of heparin or bivalirum (Angiomax).
  • Known contraindication to the use of dual anti-platelet therapy
  • Known hypersensitivity to contrast media which cannot be adequately pretreated.
  • Subject has renal insufficiency, defined as baseline creatinine level ≥ 2.0 mg/dl.
  • Subject has a known history of neutropenia (WBC <3,000/mm3) or significant anemia.
  • Subjects has a known history of coagulopathy or thrombophilia [prothrombin International Normalized Ratio (INR)>1.5, Platelet count<80,000/ μL], that has not resolved or has required treatment in the past 6 months.
  • Major bleeding within 6 months of index procedure.
  • A planned invasive surgical procedure within 30 days.
  • Undergone cardiac surgery within the past 30 days or has a planned surgical procedure within 30 days from study procedure
  • Left ventricular ejection fraction < 25%
  • The patient is in cardiogenic shock or hemodynamic unstable
  • Cerebrovascular Accident (CVA) or TIA within the past 6 months.
  • Exclusions that preclude placement of the bell balloon per the Instruction for Use
  • Subject not capable of understanding and signing the Informed Consent form.
  • Angiographic Criteria
  • Anatomical exclusions that preclude placement of the bell balloon per the Instruction for Use.
  • Target lesion inside or within 10mm of a prior stent
  • Target lesion distal to a prior placed stent
  • Severe calcification at the lesion site or proximal to it.
  • Aorto-ostial lesions
  • Bifurcation lesions (side branch diameter ≥ 2.0mm)
  • Severe coronary artery tortuosity (Angulation >450)
  • Target lesion is totally occluded, or Thrombolysis in Acute MI (TIMI flow 0) despite pre-dilatation with small caliber balloon
  • Coronary artery spasm in the absence of a significant stenosis

结局指标

主要结局

Angiographic and Device Success

时间窗: During procedure and up to 30 (+/-7) days post procedure

Defined as patent vessel with stenosis \<50% with a final TIMI flow grade 3 (visually assessed by angiography) without side branch loss, flow-limiting dissection, or angiographic thrombus and embolic material retrieval. * Thrombolysis In Myocardial Infarction (TIMI) flow grade at the end of the revascularization procedure, compared to baseline. * ST resolution level in patients with ST-Elevation Myocardial Infarction (STEMI). * Myocardial Blush Grade (MBG) at the end of procedure, compared to baseline

Performance - Device success

时间窗: During procedure and up to 30 (+/-7) days post procedure

Defined as ability to deliver, deploy, and intact retract retrieval of the study device and retrieve embolic material

The rate of major adverse cardiac events (MACE)

时间窗: Up to 30 (+/-7) days post procedure

Defined as a composite of cardiac death, all myocardial infarction (Q wave and non-Q wave), and target lesion revascularization (PCI and CABG)

次要结局

未报告次要终点

研究者

发起方
Angioslide Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验